This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Xarelto
  • /
  • An Efficacy and Safety Study for Rivaroxaban in Pa...
Clinical trial

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Read time: 1 mins
Last updated:1st Nov 2008
Identifier: NCT00809965

The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
Enrollment: 15526
Study Start Date: November 2008
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)

- Experimental:
Rivaroxaban 2.5 mg bid
- Experimental: Rivaroxaban 5 mg bid
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2014-09-17
Study type(s) Interventional
Expected enrolment 15526
Study start date 2008-11-01
Estimated primary completion date 2011-09-01

View full details